HEAD AND NECK SQUAMOUS CELL CARCINOMA HNSCC
Clinical trials for HEAD AND NECK SQUAMOUS CELL CARCINOMA HNSCC explained in plain language.
Never miss a new study
Get alerted when new HEAD AND NECK SQUAMOUS CELL CARCINOMA HNSCC trials appear
Sign up with your email to follow new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA HNSCC, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Immunotherapy plus radiation may slow returning head and neck cancer
Disease control OngoingThis study is for people whose head and neck cancer has returned or is a new tumor in the same area and cannot be removed by surgery. It tests whether adding the immunotherapy drug pembrolizumab to precise, high-dose radiation therapy can help keep the cancer from growing longer …
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA HNSCC
Phase: PHASE2 • Sponsor: RTOG Foundation, Inc. • Aim: Disease control
Last updated May 01, 2026 17:26 UTC
-
New combo therapy aims to boost immune attack on head and neck cancer
Disease control OngoingThis study tests whether adding an experimental drug (INBRX-106) to the standard immunotherapy pembrolizumab works better than pembrolizumab alone for people with advanced head and neck cancer that has spread or come back. About 410 adults whose tumors have a high level of a prot…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA HNSCC
Phase: PHASE2, PHASE3 • Sponsor: Inhibrx Biosciences, Inc • Aim: Disease control
Last updated May 01, 2026 15:57 UTC
-
New antibody combo shows promise for Hard-to-Treat cancers
Disease control OngoingThis study tests an experimental antibody called GEN1042, alone or with another cancer drug (pembrolizumab) and sometimes chemotherapy, in people with advanced solid tumors like lung, colon, melanoma, head and neck, or pancreatic cancer. The goal is to see if the treatment is saf…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA HNSCC
Phase: PHASE1, PHASE2 • Sponsor: Genmab • Aim: Disease control
Last updated Apr 30, 2026 15:51 UTC
-
New drug cocktail shows promise for tough head and neck cancers
Disease control OngoingThis study tests whether combining several drugs can shrink tumors in adults with head and neck cancer that has come back or spread. Participants receive up to three antibodies: two that help the immune system fight cancer, one that blocks tumor growth signals, and one that cuts …
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA HNSCC
Phase: PHASE1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Apr 29, 2026 15:02 UTC